280 related articles for article (PubMed ID: 29024628)
1. Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.
Lin N; Fu W; Zhao C; Li B; Yan X; Li Y
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):270-277. PubMed ID: 29024628
[TBL] [Abstract][Full Text] [Related]
2. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.
Yang L; Liu Y; Zhang N; Ding X; Zhang W; Shen K; Huang L; Zhou J; Cui S; Zhu Z; Hu Z; Xiao M
Oncotarget; 2017 May; 8(18):30395-30409. PubMed ID: 28418922
[TBL] [Abstract][Full Text] [Related]
3. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
4. DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts.
Yang L; Liu Y; Zhu L; Xiao M
Leuk Lymphoma; 2015; 56(10):2914-22. PubMed ID: 25721756
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
[TBL] [Abstract][Full Text] [Related]
6. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
Lu R; Wang P; Parton T; Zhou Y; Chrysovergis K; Rockowitz S; Chen WY; Abdel-Wahab O; Wade PA; Zheng D; Wang GG
Cancer Cell; 2016 Jul; 30(1):92-107. PubMed ID: 27344947
[TBL] [Abstract][Full Text] [Related]
8. AML-Associated Mutations in DNA Methyltransferase DNMT3A.
Khrabrova DA; Yakubovskaya MG; Gromova ES
Biochemistry (Mosc); 2021 Mar; 86(3):307-318. PubMed ID: 33838631
[TBL] [Abstract][Full Text] [Related]
9. [Functional role of DNMT3A mutation in acute myeloid leukemia].
Koya J; Kurokawa M
Rinsho Ketsueki; 2018; 59(5):602-610. PubMed ID: 29877252
[TBL] [Abstract][Full Text] [Related]
10. Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies.
Cole CB; Russler-Germain DA; Ketkar S; Verdoni AM; Smith AM; Bangert CV; Helton NM; Guo M; Klco JM; O'Laughlin S; Fronick C; Fulton R; Chang GS; Petti AA; Miller CA; Ley TJ
J Clin Invest; 2017 Oct; 127(10):3657-3674. PubMed ID: 28872462
[TBL] [Abstract][Full Text] [Related]
11. DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia.
Zhang YY; Yao DM; Zhu XW; Zhou JD; Ma JC; Yang J; Wen XM; Guo H; Lin J; Qian J
Leuk Res; 2015 Oct; 39(10):1041-7. PubMed ID: 26242829
[TBL] [Abstract][Full Text] [Related]
12. A mutational and expressional analysis of DNMT3A in acute myeloid leukemia cytogenetic subgroups.
Zare-Abdollahi D; Safari S; Movafagh A; Riazi-Isfahani S; Ghadyani M; Hashemi-Gorji F; Feyzollah HG; Nasrollahi MF; Omrani MD
Hematology; 2015 Aug; 20(7):397-404. PubMed ID: 25592687
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
14. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
[TBL] [Abstract][Full Text] [Related]
15. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
[TBL] [Abstract][Full Text] [Related]
16. Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.
Que Y; Li H; Lin L; Zhu X; Xiao M; Wang Y; Zhu L; Li D
Front Immunol; 2021; 12():653030. PubMed ID: 34093541
[TBL] [Abstract][Full Text] [Related]
17. Functional Analysis of DNMT3A DNA Methyltransferase Mutations Reported in Patients with Acute Myeloid Leukemia.
Khrabrova DA; Loiko AG; Tolkacheva AA; Cherepanova NA; Zvereva MI; Kirsanova OV; Gromova ES
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861499
[TBL] [Abstract][Full Text] [Related]
18. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Gaidzik VI; Weber D; Paschka P; Kaumanns A; Krieger S; Corbacioglu A; Krönke J; Kapp-Schwoerer S; Krämer D; Horst HA; Schmidt-Wolf I; Held G; Kündgen A; Ringhoffer M; Götze K; Kindler T; Fiedler W; Wattad M; Schlenk RF; Bullinger L; Teleanu V; Schlegelberger B; Thol F; Heuser M; Ganser A; Döhner H; Döhner K;
Leukemia; 2018 Jan; 32(1):30-37. PubMed ID: 28643785
[TBL] [Abstract][Full Text] [Related]
19. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
[TBL] [Abstract][Full Text] [Related]
20. DNMT3A in Leukemia.
Brunetti L; Gundry MC; Goodell MA
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
